151 related articles for article (PubMed ID: 17613416)
1. Radium-223 for men with hormone-refractory prostate cancer and bone metastases.
Shelley MD; Mason MD
Lancet Oncol; 2007 Jul; 8(7):564-5. PubMed ID: 17613416
[No Abstract] [Full Text] [Related]
2. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
Nilsson S; Franzén L; Parker C; Tyrrell C; Blom R; Tennvall J; Lennernäs B; Petersson U; Johannessen DC; Sokal M; Pigott K; Yachnin J; Garkavij M; Strang P; Harmenberg J; Bolstad B; Bruland OS
Lancet Oncol; 2007 Jul; 8(7):587-94. PubMed ID: 17544845
[TBL] [Abstract][Full Text] [Related]
3. Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review.
Croke J; Leung E; Segal R; Malone S
BMJ Case Rep; 2012 Nov; 2012():. PubMed ID: 23125297
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in metastatic prostate cancer.
Yigitbasi O; Ozturk U; Goktug HN; Gucuk A; Bakirtas H
Urol Oncol; 2011; 29(2):162-5. PubMed ID: 19450995
[TBL] [Abstract][Full Text] [Related]
5. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
6. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.
Nome R; Hernes E; Bogsrud TV; Bjøro T; Fosså SD
Scand J Urol; 2015 Jun; 49(3):211-7. PubMed ID: 25515952
[TBL] [Abstract][Full Text] [Related]
7. Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects.
Lewis B; Chalhoub E; Chalouhy C; Sartor O
Oncology (Williston Park); 2015 Jul; 29(7):483-8. PubMed ID: 26178336
[TBL] [Abstract][Full Text] [Related]
8. Radium-223 vs EBRT for multiple painful bone metastases: the data favor radium-223.
Vogelzang NJ
Oncology (Williston Park); 2014 Apr; 28(4):296, 298. PubMed ID: 24839800
[No Abstract] [Full Text] [Related]
9. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
Lein M; Wirth M; Miller K; Eickenberg HU; Weissbach L; Schmidt K; Haus U; Stephan C; Meissner S; Loening SA; Jung K
Eur Urol; 2007 Nov; 52(5):1381-7. PubMed ID: 17321667
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.
Parker CC; Pascoe S; Chodacki A; O'Sullivan JM; Germá JR; O'Bryan-Tear CG; Haider T; Hoskin P
Eur Urol; 2013 Feb; 63(2):189-97. PubMed ID: 23000088
[TBL] [Abstract][Full Text] [Related]
11. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
12. Radium-223 for the treatment of prostate cancer.
Hafeez S; Parker C
Expert Opin Investig Drugs; 2013 Mar; 22(3):379-87. PubMed ID: 23316941
[TBL] [Abstract][Full Text] [Related]
13. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
14. Radium-223 vs EBRT for multiple painful bone metastases: is less more?
Roach M
Oncology (Williston Park); 2014 Apr; 28(4):297-8. PubMed ID: 24839801
[No Abstract] [Full Text] [Related]
15. Targeted radionuclides for prostate cancer bone metastases.
Ito T; Bilusic M; Chen D
Urol Oncol; 2015 Jan; 33(1):2-6. PubMed ID: 25671235
[No Abstract] [Full Text] [Related]
16. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.
Nilsson S; Strang P; Aksnes AK; Franzèn L; Olivier P; Pecking A; Staffurth J; Vasanthan S; Andersson C; Bruland ØS
Eur J Cancer; 2012 Mar; 48(5):678-86. PubMed ID: 22341993
[TBL] [Abstract][Full Text] [Related]
17. Radium-223 Therapy of Bone Metastases in Prostate Cancer.
Nilsson S
Semin Nucl Med; 2016 Nov; 46(6):544-556. PubMed ID: 27825434
[TBL] [Abstract][Full Text] [Related]
18. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
[TBL] [Abstract][Full Text] [Related]
19. Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy.
Wenter V; Herlemann A; Fendler WP; Ilhan H; Tirichter N; Bartenstein P; Stief CG; la Fougère C; Albert NL; Rominger A; Gratzke C
Oncotarget; 2017 Jul; 8(27):44131-44140. PubMed ID: 28484088
[TBL] [Abstract][Full Text] [Related]
20. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
